secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001628280-25-050415
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine Q3 net loss $50.6M; cash $227M funds into 2027; AATD candidate nominated
--------------------------------------------------------------------------------

- Net loss $50.6M vs $52.5M in Q3 2024; R&D spend $44.0M (+9% YoY) driven by license costs.
- Cash and investments $227M; company expects runway into 2027 under current plans.
- Nominated PM647 as AATD development candidate; IND/CTA on track for mid-2026 with clinical data in 2027.
- Wilson's Disease program PM577 on track for IND/CTA in H1 2026; initial data expected in 2027.
- Appointed Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer to lead strategy and partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025050415/0001628280-25-050415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025050415/prme-20251107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-050415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer